261 related articles for article (PubMed ID: 24656455)
21. Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a single center experience.
Robella M; Vaira M; Marsanic P; Mellano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2013 Dec; 68(6):569-77. PubMed ID: 24193289
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
[TBL] [Abstract][Full Text] [Related]
23. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Elias D; Honoré C; Ciuchendéa R; Billard V; Raynard B; Lo Dico R; Dromain C; Duvillard P; Goéré D
Br J Surg; 2008 Sep; 95(9):1164-71. PubMed ID: 18690633
[TBL] [Abstract][Full Text] [Related]
24. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Smeenk RM; Verwaal VJ; Antonini N; Zoetmulder FA
Ann Surg; 2007 Jan; 245(1):104-9. PubMed ID: 17197972
[TBL] [Abstract][Full Text] [Related]
25. [Pseudomyxoma peritonei; a rare tumour that can be treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
Smeenk RM; Verwaal VJ; Zoetmulder FA
Ned Tijdschr Geneeskd; 2007 Feb; 151(7):418-23. PubMed ID: 17343142
[TBL] [Abstract][Full Text] [Related]
26. Postoperative pancreatic fistula after cytoreductive surgery and perioperative intraperitoneal chemotherapy: incidence, risk factors, management, and clinical sequelae.
Saxena A; Chua TC; Yan TD; Morris DL
Ann Surg Oncol; 2010 May; 17(5):1302-10. PubMed ID: 20087784
[TBL] [Abstract][Full Text] [Related]
27. [Literature review of the efficacy and safety of hyperthermic intraperitoneal perfusion chemotherapy after cytoreductive surgery in the treatment of pseudomyxoma peritonei].
Ba MC; Cui SZ; Luo FT; Ouyang WW; Tang YQ; Wu YB; Tang HS
Zhonghua Wei Chang Wai Ke Za Zhi; 2011 Feb; 14(2):132-5. PubMed ID: 21365508
[TBL] [Abstract][Full Text] [Related]
28. An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with pseudomyxoma peritonei.
Deraco M; De Simone M; Rossi CR; Cavaliere F; Di Filippo F; Vaira M; Piatti P; Kusamura S
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):35-9. PubMed ID: 16767904
[TBL] [Abstract][Full Text] [Related]
29. Upfront compared to delayed cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei is associated with considerably lower perioperative morbidity and recurrence rate.
Chua TC; Liauw W; Zhao J; Morris DL
Ann Surg; 2011 Apr; 253(4):769-73. PubMed ID: 21475018
[TBL] [Abstract][Full Text] [Related]
30. Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies.
Kusamura S; Baratti D; Deraco M
Ann Surg; 2012 Feb; 255(2):348-56. PubMed ID: 22202584
[TBL] [Abstract][Full Text] [Related]
31. [Cytoreductive surgery (peritonectomy) and intraperitoneal hyperthermic chemotherapy: an innovative and effective approach to the treatment of pseudomyxoma peritonei].
Deraco M; Kusamura S; Gronchi A
Tumori; 2003; 89(4 Suppl):54-5. PubMed ID: 12903545
[TBL] [Abstract][Full Text] [Related]
32. Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei.
Bjersand K; Mahteme H; Sundström Poromaa I; Andréasson H; Graf W; Larsson R; Nygren P
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S810-6. PubMed ID: 26193962
[TBL] [Abstract][Full Text] [Related]
33. Peritoneal surface malignancies and regional treatment: a review of the literature.
Rubino MS; Abdel-Misih RZ; Bennett JJ; Petrelli NJ
Surg Oncol; 2012 Jun; 21(2):87-94. PubMed ID: 21216590
[TBL] [Abstract][Full Text] [Related]
34. Cytoreduction including total gastrectomy for pseudomyxoma peritonei.
Sugarbaker PH
Br J Surg; 2002 Feb; 89(2):208-12. PubMed ID: 11856136
[TBL] [Abstract][Full Text] [Related]
35. Treating pseudomyxoma peritonei without heated intraperitoneal chemotherapy--a first look in New Zealand.
Wheeler BR; Reddy SK; Kenwright D; Keating JP
N Z Med J; 2014 Feb; 127(1389):31-9. PubMed ID: 24548955
[TBL] [Abstract][Full Text] [Related]
36. [Pseudomyxoma peritonei treated with complete resection and immediate intraperitoneal chemotherapy].
Elias D; Laurent S; Antoun S; Duvillard P; Ducreux M; Pocard M; Lasser P
Gastroenterol Clin Biol; 2003 Apr; 27(4):407-12. PubMed ID: 12759682
[TBL] [Abstract][Full Text] [Related]
37. Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from pseudomyxoma peritonei.
Cioppa T; Vaira M; Bing C; D'Amico S; Bruscino A; De Simone M
World J Gastroenterol; 2008 Nov; 14(44):6817-23. PubMed ID: 19058307
[TBL] [Abstract][Full Text] [Related]
38. Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.
Alves S; Mohamed F; Yadegarfar G; Youssef H; Moran BJ
Eur J Surg Oncol; 2010 Dec; 36(12):1156-61. PubMed ID: 20864306
[TBL] [Abstract][Full Text] [Related]
39. Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.
Piso P; Slowik P; Popp F; Dahlke MH; Glockzin G; Schlitt HJ
Ann Surg Oncol; 2009 Aug; 16(8):2188-94. PubMed ID: 19408049
[TBL] [Abstract][Full Text] [Related]
40. The modified Glasgow prognosis score predicts for overall and disease-free survival following cytoreductive surgery and HIPEC in patients with pseudomyxoma peritonei of appendiceal origin.
Tan GH; Novo CA; Dayal S; Chandrakumaran K; Mohamed F; Cecil T; Moran BJ
Eur J Surg Oncol; 2017 Feb; 43(2):388-394. PubMed ID: 27866811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
